Search
Acipimox
go.drugbank.com/drugs/DB09055ApprovedInvestigationalLong-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. … Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL.
Vutrisiran
go.drugbank.com/drugs/DB16699ApprovedInvestigational[A249010] More than 130 TTR mutations have been identified so far,[A249015] but the most common one is the replacement of valine with methionine at position 30 (Val30Met). … [A249010] Vutrisiran was approved by the FDA in June 2022.
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnIt is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Ferric pyrophosphate
go.drugbank.com/drugs/DB09147ApprovedInvestigationalThe ferric ion is strongly complexed by pyrophosphate.[A31979] It presents an increasing interest as this insoluble form can be milder in the gastrointestinal tract and present higher bioavailability.
Homatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedIt may also be used to prevent nausea, vomiting, and motion sickness. … Homatropine methylbromide is a quaternary ammonium muscarinic acetylcholine receptor antagonist belonging to the group of medicines called anti-muscarinics.
Mixtures: BONESPAS GOTAS COMPOSITE NFHydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedHydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain … Sensitivity to hydroxycitronellal may be identified with a clinical patch test.
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc. … (NV).
Octasulfur
go.drugbank.com/drugs/DB09353ApprovedPeople take sulfur by mouth for shortness of breath, allergies, swelling in the back of the throat (pharyngitis), high cholesterol, clogged arteries, menopause, and upper respiratory tract infections like … Sulfur seems to have an antibacterial activity. It has been also used for acne.
Mixtures: POLY-N OINTMENT, NEO-MEDROL ACNE LOTIONProducts: Sulfo lo, ZO Skin Health Sulfur MasqueBemotrizinol
go.drugbank.com/drugs/DB11206ApprovedCompared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212]. … It is claimed to be photostable, which increases its onset of action and its efficiency in providing protection against UV-rays upon topical application [A19212, A32909].
Mixtures: Dpc Pink Aura Cushion No.21, Dpc Pink Aura Cushion No.23Olodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalElevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. … Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs.
Categories: Agents to Treat Airway Disease